Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cemiplimab + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Cemiplimab is a fully human monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses. It is primarily developed for and approved in certain skin cancers but is being investigated in combination with chemotherapy for other malignancies, including pancreatic cancer. Gemcitabine is a nucleoside analog antimetabolite chemotherapy agent that inhibits DNA synthesis by incorporation into DNA and inhibition of ribonucleotide reductase, leading to cell death. The combination of cemiplimab and gemcitabine leverages both immunotherapy and cytotoxic mechanisms to treat advanced cancers such as metastatic pancreatic ductal adenocarcinoma[1][3][6][8].
- Other names
- cemiplimab-rwlcdFdC (for gemcitabine)
02
Targets
DNA polymerase familyPDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on cemiplimab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cemiplimab + gemcitabine.